Translational studies of head and neck cancer in south america and europe
Worldwide, more than 550,000 new cases of head and neck cancer (HNC) occur each year, resulting in approximately 300,000 deaths annually. It is the 6th most common cancer in both Europe and South America. A major reason for the high mortality rate for this cancer is the late stage of diagnosis for many patients. Accurate assessment of the prognosis of HNC cases also allows for appropriate treatment decisions. HEADSpAcE will bring together a consortium of 15 partners with a long and successful record of collaboration in HNC. The impact of HEADSpAcE will be to understand reasons for late diagnosis and reduce the proportion of HNC that are diagnosed at a very late stage. It will identify the most appropriate fashion for diagnosis cancer caused by human papilloma virus, and also provide genomic evidence of strong predictors of prognosis that will have the potential to improve care and reduce treatment related morbidity. We will also develop guidelines for implementation into clinical care.